Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.
暂无分享,去创建一个
J. D. de Fijter | J. Wetzels | R. Zietse | R. Gansevoort | V. Torres | D. Peters | J. Drenth | E. Meijer | P. Kappert | N. Casteleijn | T. Gevers | E. M. Spithoven | M. Salih | Hedwig M. A. D’Agnolo | D. Soonawala | F. W. Visser